GHR Foundation
  • Domains of Work
    • Global >
      • Children in Families
      • Prepare The Future
    • Local >
      • Catholic Education
      • Twin Cities Racial Equity (TCRE)
    • Biomedical >
      • Alzheimer's Initiative
  • News
  • About Us
    • The Foundation
    • History & Legacy
    • Team >
      • Staff
      • Committees
      • Board
    • Programs in Transition >
      • BridgeBuilder >
        • Overview
        • 2017 Top Ideas >
          • Peace Direct
          • BioCarbon Engineering
          • LIFT Chicago
          • Local Youth Corner Cameroon
          • NaTakallam
        • 2018 Top Ideas >
          • This is My Backyard
          • Found in Translation
          • Producers Direct
          • War Child Canada
          • My Choices Foundation
        • 2019 Top Ideas >
          • Top Manta
          • Five One Labs
          • SAMA for All
          • Talent Beyond Boundaries
          • FaithAction
      • Inter-Religious Action
      • Sister Support
    • FAQs
    • Grants & Financials
  • Contact

GHR partner Dr. Randall Bateman of Washington University School of Medicine in St. Louis elected to National Academy of Medicine

11/2/2020

0 Comments

 
Randall J. Bateman, MD, a leading Alzheimer’s disease researcher and longtime partner of GHR in our Alzheimer’s Prevention efforts, has been elected to the National Academy of Medicine – a part of the National Academy of Sciences, to which membership is considered one of the highest honors in the fields of health and medicine in the United States. 

Dr. Bateman was selected for his groundbreaking work in discovering and developing diagnostic tools for Alzheimer’s disease. GHR has been privileged to partner with Dr. Bateman on the development of a blood test for early Alzheimer’s detection, as well as on the Dominantly Inherited Alzheimer Network (DIAN), an international research partnership focused on understanding rare forms of Alzheimer’s disease caused by gene mutations. Dr. Bateman also created the Dominantly Inherited Alzheimer’s Network-Trials Unit (DIAN-TU) platform, the first clinical trial to test whether drug treatments prior to dementia can prevent Alzheimer’s.  

GHR Foundation is partnering boldly with a consortium of government, industry, academic research and other philanthropists on a game-changing undertaking – the prevention of Alzheimer’s disease. Learn more here.  
0 Comments



Leave a Reply.

    Categories

    All
    A4
    Alzheimer's
    Alzheimer's Association
    BridgeBuilder
    C2N
    Catholic Schools
    Children In Families
    COVID-19
    Develop Diagnostics
    DIAN Primary Prevention
    DIAN-TU
    Education
    Global Development
    Higher Education
    Inter-Religious Action
    La Jolla Institute
    Mayo Clinic
    Mayo Clinic Study Of Aging
    NIH-NIA
    Observational Studies
    Prepare The Future
    Prevention Trials
    Safeguarding
    Sister Support
    Twin Cities Racial Equity

    RSS Feed

CONNECT WITH US

NEWS  |  JOBS  | ​ CONTACT  
Privacy Policy  |  Terms of Use
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
©2023 GHR FOUNDATION
All Rights Reserved.